Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

BACKGROUND: Antifungal prophylaxis with a new oral tablet formulation of posaconazole may be beneficial to patients at high risk for invasive fungal disease. A two-part (Phase 1B/3) study evaluated posaconazole tablet pharmacokinetics (PK) and safety. METHODS: Patients with neutropenia following che...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Antimicrob Chemother
Autori principali: Cornely, Oliver A., Duarte, Rafael F., Haider, Shariq, Chandrasekar, Pranatharthi, Helfgott, David, Jiménez, Javier López, Candoni, Anna, Raad, Issam, Laverdiere, Michel, Langston, Amelia, Kartsonis, Nicholas, Van Iersel, Marlou, Connelly, Nancy, Waskin, Hetty
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6937013/
https://ncbi.nlm.nih.gov/pubmed/26612870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv380
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi